or Try an Advanced Search...

    Enzyme Replacement Therapies Stocks List

    Symbol Grade Name % Change
    SNY D Sanofi 5.86
    View As Page of Charts
    Related Industries: Drug Manufacturers - Major
    Related Stock Lists: Animal Health Cac 40 Cancer Chronic Kidney Disease Clopidogrel Colorectal Cancer Consumer Health Care Consumer Health Care Products Deep Vein Thrombosis Dialysis Fever Gaucher Disease Glucose Glucose Meter Health Care Products Health Sciences Healthcare Products Hepatotoxins Hypertension Influenza

    Related ETFs - A few ETFs which own one or more of the above listed Enzyme Replacement Therapies stocks.

    Symbol Grade Name Weight
    PPH C Market Vectors Pharmaceutical ETF 4.57
    VIRS D Pacer BioThreat Strategy ETF 4.06
    PID C PowerShares Intl Dividend Achievers 2.86
    PVAL A Putnam Focused Large Cap Value ETF 2.27
    SURE A AdvisorShares Insider Advantage ETF 2.26
    View all Enzyme Replacement Therapies ETFs...
    Compare ETFs
    Compare PID to PVAL Compare PPH to PID Compare VIRS to SURE

        Enzyme Replacement Therapies Stocks Recent News

        Date Stock Title
        Apr 25 SNY AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
        Apr 25 SNY Sanofi 2024 Q1 - Results - Earnings Call Presentation
        Apr 25 SNY 20 Fastest Growing Health Tech Companies in the World
        Apr 25 SNY Sanofi (SNY) Q1 2024 Earnings Call Transcript
        Apr 25 SNY Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
        Apr 25 SNY AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
        Apr 25 SNY US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
        Apr 25 SNY Sanofi Sales, Profit Beat Expectations
        Apr 25 SNY UPDATE 2-Sanofi profit slips on generic competition and currency effects
        Apr 25 SNY Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance
        Apr 25 SNY Sanofi profit slips on generic competition and currency effects
        Apr 25 SNY Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
        Apr 24 SNY What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
        Apr 23 SNY Sanofi reportedly lining up banks for consumer products spinoff
        Apr 23 SNY Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
        Apr 23 SNY Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
        Apr 23 SNY Sanofi succeeds in late-stage trial for blood disorder candidate
        Apr 23 SNY Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
        Apr 22 SNY Sanofi reportedly settles 4K Zantac cases for $100M
        Apr 22 SNY Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer
        Related Industries: Drug Manufacturers - Major
        Related Stock Lists: Animal Health Cac 40 Cancer Chronic Kidney Disease Clopidogrel Colorectal Cancer Consumer Health Care Consumer Health Care Products Deep Vein Thrombosis Dialysis Fever Gaucher Disease Glucose Glucose Meter Health Care Products Health Sciences Healthcare Products Hepatotoxins Hypertension Influenza
        Enzyme Replacement Therapies

        Enzyme Replacement Therapies (ERT) is a type of treatment used to treat certain genetic diseases caused by a lack of specific enzymes in the body. This type of therapy involves replacing the missing enzyme with a synthetic version, which can help restore normal functioning of the body. ERT is used to treat diseases such as Gaucher disease, Fabry disease, and Pompe disease.

        Browse All Tags